RBC Capital Markets this week began covering Revvity, the diagnostics and life sciences tools company, with a cautious stance. The bank assigned a “sector perform” rating and a $135 price target, signaling that it expects the stock to move roughly in line with the broader market over the next year. The main reason: two of Revvity's key businesses are losing steam as rivals step up their game.
Revvity, which was formerly part of PerkinElmer before being spun off, sells diagnostic tests, laboratory instruments, and reagents used in research and clinical settings. The company has long pitched itself as a steady grower, with management guiding for organic growth of 6% to 8% over the long run. Organic growth strips out the effects of acquisitions and currency fluctuations, giving investors a clearer view of how the underlying business is performing.
Where the slowdown is hitting
RBC's concern centers on two specific units. Euroimmun, a diagnostics business that RBC estimates accounts for roughly 27% of Revvity's sales, is one of them. Euroimmun specializes in autoimmune disease testing and has been a reliable contributor for years. But the bank says momentum there is cooling as competitors introduce newer or cheaper alternatives.
The other unit is BioLegend, which makes antibodies and reagents used in research and diagnostics. BioLegend was a major acquisition for Revvity, and it has been a growth driver. However, RBC notes that competition in this space is heating up, which could pressure pricing and market share.
For everyday investors, the takeaway is that even a company with a solid long-term growth story can hit rough patches. When a bank like RBC starts coverage with a neutral rating, it's often a signal that the easy gains may already be priced in, and that the market's expectations could be too high relative to near-term fundamentals.
What the price target means
A price target is an analyst's estimate of what a stock should be worth over the next 12 months or so. RBC's $135 target suggests that the shares are fairly valued at current levels. If the stock is trading below that, the bank sees some upside, but not enough to warrant a “buy” recommendation. A “sector perform” rating is essentially a hold—meaning RBC expects Revvity to perform in line with its sector peers, not dramatically better or worse.
This kind of cautious initiation is common when a company's growth is decelerating. Investors often pay a premium for companies that can consistently grow at 6% to 8%, but if that growth starts to slip, the premium can shrink. RBC's analysis suggests that the market may be underestimating the competitive pressures facing Euroimmun and BioLegend.
What it means for investors
For those who own Revvity shares, this news is a reminder to keep an eye on the company's quarterly results, especially any updates on those two divisions. If growth at Euroimmun or BioLegend slows more than expected, the stock could face headwinds. On the other hand, if the company can fend off competitors and maintain its growth trajectory, the current valuation might look attractive.
It's also worth noting that Revvity operates in the broader diagnostics and life sciences tools industry, which has seen mixed demand recently. Some segments, like research tools, have been affected by budget cuts at academic institutions and biotech companies, while clinical diagnostics have been more resilient. The company's ability to navigate these crosscurrents will be key.
RBC's initiation is just one analyst's view, but it adds to a growing chorus of caution around the stock. Investors should weigh this against the company's own guidance and other analysts' opinions before making any decisions. As always, it's important to remember that no single rating or price target should drive an investment choice; a diversified portfolio and a long-term perspective are more reliable guides.
For more on how similar companies are navigating growth challenges, see our coverage of Medtronic's raised forecast and the broader cooling in US factory growth.
